Dosing is now underway in an IPF clinical trial testing the inhaled therapy LTI-03, following the lifting of an FDA hold late last year.
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., March 11, 2026--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the New England Journal of ...
Researchers from the US identified transcriptomic differences related to sex in patients with idiopathic pulmonary fibrosis.
DLCO declined earliest, falling measurably about 10 years before the defined onset. By five years before onset, DLCO had ...
The complex and redundant biology underlying fibrosis is widely believed to contribute to the limited effectiveness of single-target approaches. “Fibrosis is a biologically complex, organ-specific ...
Trevi Therapeutics (TRVI) advances Haduvio for IPF cough/RCC; Phase 2 IPF data strong, but funding, safety & opioid-label ...
-- BI 765423 has been developed to target IL-11, a key driver of fibrosis -- New study will investigate potential of BI 765423 to improve lung function for patients with idiopathic pulmonary fibrosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results